Sentiment can be difficult to predict, and when some of the sector leaders are trading at valuations well above historical norms, the situation gets all the more volatile. Such would seem to be the case with Stryker (Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other th ...

Sentiment can be difficult to predict, and when some of the sector leaders are trading at valuations well above historical norms, the situation gets all the more volatile. Such would seem to be the case with Stryker (Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other th ...

近日， 史赛克 S tryker 在内部沟通及高管社交媒体披露了一系列管理层调整。 这轮人事变动，延续了公司此前已公布的高层任命安排，涉及骨科、器械以及外科 技术等多个核心业务板块，也进一步明确了 Stryker 在新一阶段增长周期中的组织架构与管理分工。 整体来看，此次调整并非孤立事件，而是围绕集团层面高管晋升后，对关键业务单元进行的系统性衔接与补位，体现出公司在保持业务连续性的同时，对内部人才 梯队的持续提拔与轮岗安排。 # 围绕集团高管 晋升 展开的组织 调整 本轮人事变动的背景，是 Stryker 于 2025 年 12 月宣布的一项重要任命： Spencer Stiles 被任命为公司总裁兼首席运营官（President and COO） ，该任命将于 2026 年 1 月 1 日正式生效。 根据公司公告，Stiles 将在新角色中负责 Stryker 的全球业务运营、整体战略以及并购事务。Stryker 董事长兼首席执行官 Kevin Lobo 在公告中表示，这一任命将有 助于公司在现有多元化产品组合基础上，持续保持增长动能，并进一步强化运营执行能力。 随着 Spencer Stiles 升任集团 ...

Key Points Raymond James analyst Jayson Bedford upgrades Stryker stock to outperform today. The medical devices stock has grown sales at 10% or better for five straight years. 10 stocks we like better than Stryker › Stryker (NYSE: SYK) stock is hopping Tuesday morning, up 3.2% through 11:45 a.m. ET, after Raymond James analyst Jayson Bedford called the company "one of the highest quality stocks in large cap MedTech" -- and upgraded it. Bedford predicts Stryker stock will hit $418 within a year, and ...

Portage, Michigan, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will report financial results for its fourth quarter and full year 2025 on Thursday, January 29, 2026. A press release will be issued at approximately 4:05 p.m. ET and available at Stryker - Press Releases that day. The press release will include summary financial information for the company’s fourth quarter and full year that ended December 31, 2025. Stryker will host a webcast at 4:30 p.m. ET on Thursday, January 29, ...

Investors looking for stocks in the Medical - Products sector might want to consider either Envista (NVST) or Stryker (SYK) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The proven Zacks Rank puts an emphasis on earni ...

Portage, Michigan-based Stryker Corporation (SYK) is a leading global medical technology company specializing in orthopaedics, MedSurg, and neurotechnology solutions, serving hospitals and healthcare providers worldwide. Valued at $135.7 billion by market cap, the company is best known for its joint-replacement implants, surgical equipment, and advanced technologies, including the Mako robotic-assisted surgery platform, which enhances procedural precision and efficiency. The Medtech giant is expected to ...

Key Takeaways Intuitive Surgical's da Vinci platform is fueling over 20% procedure growth across 10,800 systems worldwide.SYK's robotics business supports growth but remains part of its broader, diversified MedTech portfolio.ISRG derives about 85% of revenues from recurring sources, supporting strong margins as system use expands.Intuitive Surgical (ISRG) and Stryker (SYK) are two of the most influential players in global MedTech, each benefiting from long-term procedural growth, hospital technology adoptio ...

Stryker Corporation (NYSE:SYK) is one of the best healthcare AI stocks to buy now. On December 11, Citi cut the price target on Stryker Corporation (NYSE:SYK) from $455 to $420, while maintaining a Buy rating on the shares. This adjustment, the firm said, is part of a sector-wide adjustment as it formulates its 2026 outlook. Citi Cuts Stryker (SYK) PT, Maintains Buy Amid Leadership Changes Independently of the analyst action, on December 11, Stryker’s Board of Directors declared a $0.88 per share quarter ...

Upgrades - Keefe Bruyette upgraded Bain Capital Specialty Finance (BCSF) to Outperform from Market Perform with an unchanged price target of $16, citing attractive entry point for shares [2] - JPMorgan upgraded Paccar (PCAR) to Overweight from Neutral with a price target of $133, increased from $108, due to offsetting tariff-related headwinds following the latest Section 232 proclamation [3] - Wells Fargo upgraded Generac (GNRC) to Overweight from Equal Weight with a price target of $195, up from $186, highlighting a "near-free call option" on data center growth after recent share pullback [4] - Barclays upgraded Cummins (CMI) to Overweight from Equal Weight with a price target of $546, increased from $515, reflecting new emissions rules and reduced R&D expenses [5] - Citizens upgraded Stryker (SYK) to Outperform from Market Perform with a price target of $440, citing reasonable valuation at current share levels [5] Downgrades - Wedbush downgraded Lyft (LYFT) to Underperform from Neutral with a price target of $16, down from $20, due to risks from autonomous vehicle disruption in the U.S. ridesharing market [6] - JPMorgan downgraded Lockheed Martin (LMT) to Neutral from Overweight with a price target of $515, up from $465, based on out-year cash flow estimates being below consensus [6] - Raymond James downgraded Allegiant Travel (ALGT) to Outperform from Strong Buy with a price target of $98, up from $78, citing valuation concerns after recent share strength [6] - Deutsche Bank downgraded Elevance Health (ELV) to Hold from Buy with a price target of $320, down from $332, due to reduced estimates and challenging macro environment [6] - Williams Trading downgraded Birkenstock (BIRK) to Hold from Buy with a price target of $51, down from $75, following earnings report and lack of clarity from management [6]